ACTRN12618001171202已完成2 期
Changes in sputum procalcitonin with Bactek -O sublingual vaccine treatment in adult patients with non-cystic fibrosis bronchiectasis: A pilot study
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 46
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Aged 18 years or over.
- •Able to provide written informed consent.
- •Able to provide spontaneous sputum sample at visit 2 (week 0).
- •High-resolution CT scan (HRCT) diagnosis of bronchiectasis; CT scan performed within the past 5 years
- •Clinically stable during baseline period, which is 4 weeks prior to randomisation (as defined by the absence of clinical worsening beyond normal daily variation, with no need for increasing habitual medications or taking antibiotics or prednisone and stable spirometry).
- •History of at least one pulmonary exacerbation requiring antibiotic treatment in the past 12 months. Patients with asthma and COPD will be included if the primary diagnosis is bronchiectasis.
排除标准
- •Oral or intravenous antibiotic treatment (including macrolides) within 4 weeks prior to commencing study drug.
- •Patients taking continuous oral corticosteroids (> 6 weeks) or immunosuppressive agents (e.g. azathioprine, methotrexate, cyclophosphamide).
- •Bronchiectasis exacerbation or respiratory infection requiring oral or intravenous antibiotic or steroid treatment within 4 weeks prior to commencing study drug.
- •Patients with a history of non-adherence with medications.
- •Patients with significant medical conditions other than bronchiectasis.
- •o A significant disease is defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient’s ability to participate in the study.
- •Patients with cystic fibrosis.
- •Patients with hypo-gammaglobulinaemia.
- •Patients with primary ciliary dyskinesia.
- •Patients with allergic bronchopulmonary aspergillosis (total IgE >420 IU/mL and aspergillus specific IgE level of +3 or +4, and proximal bronchiectasis on HRCT).
- •Patients with evidence of an active or suspected cancer, or a history of malignancy where the risk of recurrence is greater than or equal to 20% within 2 years judged by the treating physician (patients with basal cell carcinoma and squamous cell carcinoma are allowed). Patients who have undergone resection, radiation therapy or chemotherapy within 6 months prior to the first dose of the study drug or the expectation that such treatment will be required at any time during the study will also be excluded.
- •Pregnant or lactating women.
- •Participation in a separate clinical or device trial within 4 weeks prior to screening.
- •Allergy to any of the components of Bactek-O
- •Patients with chronic bacterial infection of Pseudomonas aeriginosa. This is defined by positive culture from standard microbiology from the lower airways of the same Pseudomonas aeriginosa on two or more occasions at least three months apart over one year in stable state.
研究者
相似试验
已完成
不适用
Verifying a parameter in saliva in three different conditionsCTRI/2022/04/042306Ragulapadu chintaginjala Rupa tejaswini80
已完成
不适用
Clinical significance of serum procalcitonin and presepsin in patients with acute cholangitisacute cholangitisJPRN-UMIN000016437Department of Gastroenterology and Hepatology, Kinki University Faculty of Medicine50
已完成
2 期
The role of procalcitonin in sepsisCondition 1: Sepsis. Condition 2: procalcitonin.Sequelae of infectious and parasitic diseasesAbnormal findings on examination of blood, without diagnosisB90-B94R70-R79IRCT201102065774N1vice-chancellor for research of Shahid Beheshti University of Medical Sciences150
已完成
不适用
Prospective study of the utility of procalcitonin (PCT) in patients with pneumonia.community-acquired pneumonia (CAP) nursing and healthcare-associated pneumonia (NHCAP)JPRN-UMIN000011566Health Promoting Association for Respiratory Medicine of Nishi-Nippon1,000
已完成
不适用
Effects of procalcitonin-guided antimicrobial stewardship on reduction of antibiotical use in patients with severe sepsis or septic shock: a retrospective analysis.A41.9R57.2Sepsis, unspecifiedSeptic shockDRKS00003490Klinik für Anästhesiologie , operative Intensivmedizin und SchmerztherapieKrankenhaus Düren141